Subcutaneous Panniculitis-like T-Cell Lymphoma: Symptoms & Treatment
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- These findings primarily impact individuals with established cardiovascular disease who are considering or currently using semaglutide for weight loss.
Ozempic and Cardiovascular Risk: new Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo.The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years.While semaglutide demonstrated significant weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
the Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the trial population specifically included individuals with pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease. The average weight loss in the semaglutide group was ample – approximately 15% of their initial body weight.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Major Adverse Cardiovascular Event) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.7 | 2.9 | 1.29 |
| Non-Fatal Stroke | 2.6 | 1.7 | 1.55 |
| Non-Fatal Heart Attack | 3.4 | 2.6 | 1.31 |
Who is Affected? Understanding the Risk Profile
These findings primarily impact individuals with established cardiovascular disease who are considering or currently using semaglutide for weight loss. It does *not* necessarily mean the drug is unsafe for everyone. Patients without pre-existing heart conditions may experience a different risk-benefit profile. However, the study highlights the importance of a thorough cardiovascular risk assessment before initiating semaglutide therapy, even in individuals without known heart disease.
The SELECT trial included participants with a Body Mass Index (BMI) of 27 or higher, and at least one cardiovascular event in the past. This specific population is now under increased scrutiny, and healthcare providers will need to carefully weigh the potential benefits of weight loss against the potential cardiovascular risks.
Why Does This Matter? The Implications for Obesity Treatment
Semaglutide, marketed as Ozempic and Wegovy, has become a widely prescribed medication for weight loss, lauded for its effectiveness. These results introduce a critical nuance to that narrative. The trial underscores that weight loss medications are not without potential risks, and a one-size-fits-all approach is inappropriate. The focus must shift towards personalized medicine, considering individual cardiovascular risk factors.